Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin receives US FDA tentative marketing approval for generic Descovy tablets
Details : Emtricitabine & tenofovir alafenamide is a generic equivalent of Descovy. This combination is NRT-inhibitor. It is indicated for HIV-1 Infection in adults & pediatric patients.
Product Name : Descovy-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2024
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Expands Gilead's Vemlidy Indication To Treat Chronic HBV in Pediatric Patients
Details : Vemlidy (tenofovir alafenamide) is approved for chronic hepatitis B in pediatric patients (6+ years) with compensated liver disease.
Product Name : Vemlidy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CHAI
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to accelerate the development of an investigational dispersible pediatric formulation containing Descovy (emtricitabine) and tenofovir alafenamide (F/TAF).
Product Name : Descovy
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CHAI
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval from USFDA for Tenofovir Alafenamide Tablets
Details : Tenofovir alafenamide accumulates more in peripheral blood mononuclear cells compared to red blood cells. Once activated, it acts with different mechanisms including the inhibition of viral polymerase, causing chain termination and the inhibition of vira...
Product Name : Vemlidy-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2023
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In HBV, data presented will highlight the long-term results of switching to Vemlidy® (tenofovir alafenamide 25 mg, TAF) for HBV prophylaxis in post-liver transplant patients with chronic kidney disease, providing sustained improvements in bone and renal...
Product Name : Vemlidy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vemlidy (tenofovir alafenamide) is a novel, targeted prodrug of tenofovir that was previously approved by the FDA in 2016 as a once-daily treatment for adults with chronic HBV infection with compensated liver disease.
Product Name : Vemlidy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JNJ-3989,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
Details : JNJ-3989 is a sub-cutaneous, ribonucleic acid interference (RNAi) therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside a...
Product Name : JNJ-3989
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : JNJ-3989,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable